IP Library Granted Patent US 7,550,145
Granted Patent B2
US 7,550,145 · App. 10/265,083 · Granted Jun 23, 2009

Adjuvant compositions

Assignee: Novarttis Vaccines and Diagnostics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,550,145
App. No.
10/265,083
Granted
Jun 23, 2009
Kind
B2
Abstract

Adjuvant compositions comprising type 1 interferon inducers, such as double-stranded RNA, in combination with antigen delivery systems and/or immunostimulatory molecules, such as immunostimulatory nucleic acid sequences, for enhancing the immune response of a coadministered antigen, are described.

Claims (10)

1. A composition comprising: (1) dsRNA, wherein the dsRNA is polyriboinosinic-polyribocytidylic acid (poly[rI-rC]), polyriboguanylic-polyribocytidylic acid (poly[rG-rC]) or polyriboadenylic-polyribouridylic acid (poly[rA-rU]); and (2) an HCV E1E2 polypeptide that comprises a sequence of amino acids with at least 90% sequence identity to the contiguous sequence of amino acids depicted at positions 20-637 of SEQ ID NO:2, with the proviso that the HCV E1E2 polypeptide comprises the amino acid sequence of SEQ ID NO:4 at a position corresponding to amino acids 218-238 of SEQ ID NO:2, wherein said polypeptide elicits an immune response against HCV,

wherein said dsRNA and/or said HCV E1E2 polypeptide are adsorbed to a microparticle, and further wherein the immune response to the composition is increased as compared to the immune response to a composition comprising the HCV E1E2 polypeptide without the dsRNA and/or the microparticle.

2. The composition of claim 1 , wherein the dsRNA is poly[rI-rC].

3. The composition of claim 2 , wherein the microparticle comprises a polymer selected from the group consisting of a poly(α-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, and a polyanhydride.

4. The composition of claim 3 , wherein the microparticle comprises poly(D,L-lactide-co-glycolide) (PLG).

5. The composition of claim 4 , wherein the polypeptide is adsorbed to the microparticle.

6. The composition of claim 4 , wherein the dsRNA is adsorbed to the microparticle.

7. The composition of claim 5 , wherein the dsRNA is adsorbed to the microparticle.

8. The composition of claim 1 , wherein the microparticle comprises 3-(trimethylsilyl)-1-propanesulfonic acid (DSS).

9. The composition of claim 1 , wherein the microparticle comprises hexadecyl trimethyl ammonium bromide (CTAB).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2016
From: NOVARTIS VACCINES AND DIAGNOSTICS INC
To: GLAXOSMITHKLINE BIOLOGICALS SA
Reel/Frame 037929/0368 →
CHANGE OF NAME Recorded May 11, 2009
From: CHIRON CORPORATION
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Reel/Frame 022663/0407 →
Continuity (3)
Provisional Application 6032692900 · Oct 3, 2001
Provisional Application 6037354700 · Apr 17, 2002
Related Publication 20030170273A1 · Sep 11, 2003